Celldex reports Phase IIb data for CDX-011

Celldex Therapeutics Inc. (NASDAQ:CLDX) reported data from the Phase IIb EMERGE trial showing that glembatumumab vedotin ( CDX-011) led to an overall response rate of 19% vs. 14% for chemotherapy in patients with advanced, refractory or resistant glycoprotein NMB ( GPNMB)-expressing breast cancer. In patients with triple-negative breast cancer, CDX-011 led to an ORR of 21% vs. 0% for chemotherapy, and in patients whose tumors had high GPNMB expression, CDX-011 led to an ORR of 32% vs. 13% for chemotherapy. In patients with both triple-negative cancer and high GPNMB expression, the product led to an ORR of 36% vs. 0% for chemotherapy. The open-label trial enrolled 117 evaluable patients. ...